William McCulloch

3.2k total citations · 3 hit papers
87 papers, 2.5k citations indexed

About

William McCulloch is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, William McCulloch has authored 87 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 21 papers in Cancer Research and 17 papers in Oncology. Recurrent topics in William McCulloch's work include Cancer, Lipids, and Metabolism (15 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Histone Deacetylase Inhibitors Research (12 papers). William McCulloch is often cited by papers focused on Cancer, Lipids, and Metabolism (15 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Histone Deacetylase Inhibitors Research (12 papers). William McCulloch collaborates with scholars based in United States, United Kingdom and Poland. William McCulloch's co-authors include Cedric J. Pearce, Nicholas H. Oberlies, Karen M. VanderMolen, George Kemble, Sean Whittaker, Tadeusz Robak, Marie O’Farrell, Madeleine Duvic, Adam Lerner and Youn H. Kim and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

William McCulloch

80 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

2021 192 citations Gerald S. Falchook, Jeffrey R. Infante et al. EClinicalMedicine profile →
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

2021 163 citations Rohit Loomba, Stephen A. Harrison et al. profile →
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

2024 44 citations Rohit Loomba, Pierre Bédossa et al. The Lancet. Gastroenterology & hepatology profile →

Peers

Countries citing papers authored by William McCulloch

Since Specialization

Citations

This map shows the geographic impact of William McCulloch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William McCulloch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William McCulloch more than expected).

Fields of papers citing papers by William McCulloch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William McCulloch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William McCulloch. The network helps show where William McCulloch may publish in the future.

Co-authorship network of co-authors of William McCulloch

This figure shows the co-authorship network connecting the top 25 collaborators of William McCulloch. A scholar is included among the top collaborators of William McCulloch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William McCulloch. William McCulloch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial breakdown → 2024 ·The Lancet. Gastroenterology & hepatology ·Rohit Loomba, Pierre Bédossa, Katharine Grimmer, George Kemble, Eduardo B. Martins, William McCulloch, Marie O’Farrell, (unknown), (unknown), Eric Lawitz, Madhavi Rudraraju, Stephen A. Harrison	44
2	Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation 2023 ·ACS Nano ·Aaron H. Colby, (unknown), Amit Patwa, Rong Liu, Beth Hollister, William McCulloch, Joanna E. Burdette, Cedric J. Pearce, (unknown), Yolonda L. Colson, Kebin Liu, Mark W. Grinstaff	11
3	Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex 2021 ·Cell Death and Disease ·Scott J. Weir, Prasad Dandawate, David Standing, (unknown), Prabhu Ramamoorthy, (unknown), (unknown), Amanda E. Brinker, Benjamin L. Woolbright, (unknown), (unknown), William McCulloch, Michael Dalton, Gregory A. Reed, (unknown), Roy A. Jensen, John A. Taylor, Shrikant Anant	11
4	First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors breakdown → 2021 ·EClinicalMedicine ·Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, (unknown), Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris	192
5	Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Scott J. Weir, (unknown), (unknown), Amanda E. Brinker, Prabhu Ramamoorthy, (unknown), (unknown), (unknown), (unknown), Michael J. McKenna, William McCulloch, Michael Dalton, Gregory A. Reed, Roy A. Jensen, (unknown), Shrikant Anant, John A. Taylor	17
6	Abstract 5882: Bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer 2018 ·Cancer Research ·Scott J. Weir, (unknown), (unknown), (unknown), Prabhu Ramamoorthy, (unknown), (unknown), Michael J. McKenna, William McCulloch, (unknown), Amanda E. Brinker, (unknown), Roy A. Jensen, John A. Taylor, Shrikant Anant	2
7	Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target 2017 ·Pharmacology & Therapeutics ·Douglas Buckley, Gregory Duke, Timothy S. Heuer, Marie O’Farrell, Allan S. Wagman, William McCulloch, George Kemble	151
8	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma 2015 ·Leukemia & lymphoma ·Ellen J. Kim, Youn H. Kim, Alain H. Rook, Adam Lerner, Madeleine Duvic, Sunil Reddy, Tadeusz Robak, Jürgen C. Becker, А. В. Самцов, William McCulloch, Joel Waksman, Sean Whittaker	17
9	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin 2012 ·Leukemia & lymphoma ·Youn H. Kim, Marie‐France Demierre, Ellen J. Kim, Adam Lerner, Alain H. Rook, Madeleine Duvic, Tadeusz Robak, А. В. Самцов, William McCulloch, Suephy C. Chen, Joel Waksman, Jean Nichols, Sean Whittaker	35
10	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma 2010 ·Journal of Clinical Oncology ·Sean Whittaker, Marie‐France Demierre, Ellen J. Kim, Alain H. Rook, Adam Lerner, Madeleine Duvic, Julia Scarisbrick, Sunil Reddy, Tadeusz Robak, Jürgen C. Becker, А. В. Самцов, William McCulloch, Youn H. Kim	480
11	Issues in Clinical Practice: Dressings 2002 ·G. Duncan, (unknown), William McCulloch	3
12	Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer 1994 ·Cancer Chemotherapy and Pharmacology ·Elizabeth Poplin, Patricia LoRusso, Jacob J. Lokich, John J. Gullo, Philip D. Leming, Joseph J. Schulz, (unknown), William McCulloch, Laurence H. Baker, Philip S. Schein	34
13	A Phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies 1992 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Robert L. Krigel, (unknown), Robert L. Comis, (unknown), (unknown), William McCulloch, (unknown)	10
14	Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. 1992 ·Journal of Clinical Oncology ·Nancy E. Kemeny, Jessica Conti, Karen Seiter, Donna Niedzwiecki, J F Botet, (unknown), (unknown), (unknown), William McCulloch	20
15	New Protective Agents for Bone Marrow in Cancer Therapy 1991 ·Cancer Investigation ·William McCulloch, (unknown), Philip S. Schein	17
16	Public Health and regulatory veterinary medicine 1983 ·Journal of Veterinary Medical Education ·Carol Hampton, (unknown), John C. New, (unknown), William McCulloch, Howard R. Pollio	0
17	The human-animal bond in the public health curriculum 1983 ·Journal of the American Veterinary Medical Association ·William McCulloch, Norman D. Heidelbaugh, (unknown), L.K. Bustad	1
18	Human Infections Associated with Waterborne Leptospires, and Survival Studies on Serotype pomona 1971 ·Journal of the American Veterinary Medical Association ·(unknown), Jack A. Heinemann, William McCulloch, (unknown)	22
19	The University and the City 1970 ·Journal of the American Veterinary Medical Association ·William McCulloch, C. Richard Dorn, D. C. Blenden	1
20	Isolation of pathogenic leptospires from waters used for recreation. 1966 ·PubMed Central ·(unknown), William McCulloch	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact